吉大一院靳凤艳团队研究入选 2025 中国十大医学研究和血液领域十大医学研究

Core Insights - The research led by the team of Jin Fengyan from Jilin University First Hospital has been recognized as one of the "Top Ten Medical Researches in the Blood Field for 2025," highlighting a significant breakthrough in the clinical treatment of primary plasma cell leukemia (pPCL) [1][2] - This recognition is part of an annual evaluation by Mace Medical, which has been conducted for eight consecutive years, emphasizing the originality and impact of the selected research [1] Group 1 - The evaluation process involved selecting 15 studies from numerous submissions, which were then narrowed down to the top 10 through online voting, ensuring transparency and public engagement [1] - The research focuses on pPCL, the most aggressive subtype of multiple myeloma, which has the poorest prognosis, addressing the limitations of existing staging systems and the challenges of personalized treatment [1] - The team developed a novel pPCL-specific staging system (PSS) using real-world data from 26 centers, which incorporates easily obtainable clinical variables such as LDH, thrombocytopenia, and cytogenetic abnormalities [1] Group 2 - The PSS system breaks the constraints of current risk stratification models, providing a more accurate prediction of patient survival outcomes and serving as a critical tool for formulating targeted treatment strategies [1] - The research demonstrates the scientific strength of Jin Fengyan's team and signifies a major advancement in clinical research within the blood field in China, contributing to global pPCL diagnosis and treatment efforts [2]